NCT06562894Phase 2Not yet recruiting
Study to Evaluate Safety and Efficacy of SYHX1901 Tablets in Severe Alopecia Areata Patients
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of SYHX1901 Tablets in the Treatment of Severe Alopecia Areata
In the register
The register attaches this trial to SYHX1901 (CSPC Pharmaceutical Group), currently at “Phase 2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Not yet recruiting
- Declared phase
- Phase 2
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Participants (registry)
- 156
- Start
- May 2025 (planned)
- Primary completion
- May 2027 (planned)
- Study completion
- November 2027 (planned)
- Last registry update
- June 2025
- Countries
- —
Conditions studied: Severe Alopecia Areata
Interventions: SYHX1901, Placebo
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.